Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations

References

• Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, etal. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA. 2002; 99(21): 13675–80. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Switaj P, Anczewska M, Chrostek A, Sabariego C, Cieza A, Bickenbach J, etal. Disability and schizophrenia: A systematic review of experienced psychosocial difficulties. BMC Psychiatry. 2012; 12: 193. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, ‘just the facts’ 4. Clinical features and conceptualization. Schizophr Res. 2009; 110(1–3): 1–23. [PubMed Abstract].
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–76. [PubMed Abstract].
   Google Scholar
• Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol Rep. 1962; 10: 799–812.
   Web of Science ®Google Scholar
• Singh MM, Kay SR. Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia. Implications for a neuropharmacological model. Neuropsychobiology. 1979; 5(2): 74–86. [PubMed Abstract].
   Google Scholar
• Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP. Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res. 1994; 52(3): 295–303. [PubMed Abstract].
   Google Scholar
• Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: Replication across samples. Schizophr Res. 1995; 14(3): 229–34. [PubMed Abstract].
   Google Scholar
• Lancon C, Auquier P, Nayt G, Reine G. Stability of the five-factor structure of the positive and negative syndrome scale (PANSS). Schizophr Res. 2000; 42(3): 231–9. [PubMed Abstract].
   Google Scholar
• Lee KH, Harris AW, Loughland CM, Williams LM. The five symptom dimensions and depression in schizophrenia. Psychopathology. 2003; 36(5): 226–33. [PubMed Abstract].
   Google Scholar
• Fresan A, Fuente-Sandoval C, Loyzaga C, Garcia-Anaya M, Meyenberg N, Nicolini H, etal. A forced five-dimensional factor analysis and concurrent validity of the positive and negative syndrome scale in Mexican schizophrenic patients. Schizophr Res. 2005; 72(2–3): 123–9. [PubMed Abstract].
   Google Scholar
• Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis. Schizophr Res. 2011; 131(1–3): 75–81. [PubMed Abstract].
   Google Scholar
• Lehoux C, Gobeil MH, Lefèbvre AA, Maziade M, Roy MA. The five-factor structure of the PANSS: A critical review of its consistency across studies. Clin Schizophr Relat Psychoses. 2009; 3(2): 103–10.
   Google Scholar
• Van den Oord EJ, Rujescu D, Robles JR, Giegling I, Birrell C, Bukszar J, etal. Factor structure and external validity of the PANSS revisited. Schizophr Res. 2006; 82(2–3): 213–23. [PubMed Abstract].
   Google Scholar
• Emsley R, Rabinowitz J, Torreman M. The factor structure for the positive and negative syndrome scale (PANSS) in recent-onset psychosis. Schizophr Res. 2003; 61(1): 47–57. [PubMed Abstract].
   Google Scholar
• Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997; 17(4): 298–307. [PubMed Abstract].
   Google Scholar
• Dollfus S, Petit M, Lesieur P, Menard JP. Principal component analysis of PANSS and SANS-SAPS global ratings in schizophrenic patients. Eur Psychiatry. 1991; 6: 251–9.
   Google Scholar
• Lykouras L, Oulis P, Daskalopoulou E, Psarros K, Christodoulou GN. Clinical subtypes of schizophrenic disorders: A cluster analytic study. Psychopathology. 2001; 34(1): 23–8. [PubMed Abstract].
   Google Scholar
• Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, etal. The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004; 71(1): 83–95. [PubMed Abstract].
   Google Scholar
• Lenert LA, Rupnow MF, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes. 2005; 3: 57. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004; 71(1): 155–65. [PubMed Abstract].
   Google Scholar
• Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, etal. Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. Clinicoecon Outcomes Res. 2011; 3: 79–87. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, etal. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006; 163(12): 2080–9. [PubMed Abstract].
   Google Scholar
• Bebbington PE, Angermeyer M, Azorin JM, Brugha T, Kilian R, Johnson S, etal. The European Schizophrenia Cohort (EuroSC): A naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol. 2005; 40(9): 707–17. [PubMed Abstract].
   Google Scholar
• Heider D, Angermeyer MC, Winkler I, Schomerus G, Bebbington PE, Brugha T, etal. A prospective study of quality of life in schizophrenia in three European countries. Schizophr Res. 2007; 93(1–3): 194–202. [PubMed Abstract].
   Google Scholar
• Heider D, Bernert S, Konig HH, Matschinger H, Hogh T, Brugha TS, etal. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom – findings from the European Schizophrenia Cohort (EuroSC). Eur Psychiatry. 2009; 24(4): 216–24. [PubMed Abstract].
   Google Scholar
• Marwaha S, Johnson S, Bebbington P, Angermeyer MC, Brugha T, Azorin JM, etal. Correlates of subjective quality of life in people with schizophrenia: Findings from the EuroSC study. J Nerv Ment Dis. 2008; 196(2): 87–94. [PubMed Abstract].
   Google Scholar
• Marwaha S, Johnson S, Bebbington PE, Angermeyer MC, Brugha TS, Azorin JM, etal. Predictors of employment status change over 2 years in people with schizophrenia living in Europe. Epidemiol Psichiatr Soc. 2009; 18(4): 344–51. [PubMed Abstract].
   Google Scholar
• Roick C, Heider D, Bebbington PE, Angermeyer MC, Azorin JM, Brugha TS, etal. Burden on caregivers of people with schizophrenia: Comparison between Germany and Britain. Br J Psychiatry. 2007; 190: 333–8. [PubMed Abstract].
   Google Scholar
• Schomerus G, Heider D, Angermeyer MC, Bebbington PE, Azorin JM, Brugha T, etal. Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC). Soc Psychiatry Psychiatr Epidemiol. 2007; 42(8): 617–22. [PubMed Abstract].
   Google Scholar
• Schomerus G, Heider D, Angermeyer MC, Bebbington PE, Azorin JM, Brugha T, etal. Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: Results from the European Schizophrenia Cohort (EuroSC). Psychol Med. 2008; 38(4): 591–7. [PubMed Abstract].
   Google Scholar
• Verdoux H. The current state of adult mental health care in France. Eur Arch Psychiatry Clin Neurosci. 2007; 257(2): 64–70. [PubMed Abstract].
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV [Internet]. 1994; Washington, DC: American Psychiatric Association. 4th ed. p. 866. Available from: http://www.psychiatryonline.com/DSMPDF/dsm-iv.pdf [cited 2010 March 8].
   Google Scholar
• Journal Officiel de la République Française Assemblée Nationale et Sénat. CNIL: Act n 78–17 of 6 January 1978 on Data Processing, Data Files and Individual Liberties amended by the Act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data. 2004
   Google Scholar
• World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects (revised October 7, 2000). HIV Clin Trials. 2001; 2: 92–5.
   Google Scholar
• Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973; 33: 613–19.
   Web of Science ®Google Scholar
• Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012; 137(1–3): 246–50. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1): 159–74. [PubMed Abstract].
   Google Scholar
• Janicak PG, Glick ID, Marder SR. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: A pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009; 70(1): 25–35. [PubMed Abstract].
   Google Scholar
• Nakaya M, Suwa H, Ohmori K. Latent structures underlying schizophrenic symptoms: A five-dimensional model. Schizophr Res. 1999; 39(1): 39–50. [PubMed Abstract].
   Google Scholar
• van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, de Haan L, etal. The five-factor model of the positive and negative syndrome scale I: Confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr Res. 2006; 85(1–3): 273–279. [PubMed Abstract].
   Google Scholar